Anti-Mouse CD370 (CLEC9A/DNGR-1) [Clone 1F6] — Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse CD370 (CLEC9A/DNGR-1) [Clone 1F6] — Purified in vivo PLATINUM™ Functional Grade
Product No.: I-2020
Clone 1F6 Target CD370 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names CD370, DNGR-1, C-Type Lectin Domain Family 9 Member A Isotype Mouse IgG1 Applications FC , IF , in vivo , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen RBL-2H3 cells expressing mouse DNGR-1 fused to an HA epitope Product Concentration ≥ 5.0 mg/ml Endotoxin Level ≤ 0.5 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893830 Applications and Recommended Usage? Quality Tested by Leinco FC WB Additional Applications Reported In Literature ? IF Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This clone 1F6 monoclonal antibody recognizes a direct epitope on mouse DNGR1/CLEC9A for CD8+ dendritic cells, which can be exploited for tumor therapy, whilst also recognizing necrotic cells. This antibody can recognize both the short and long isoform of DNGR-1, which varies in a segment of the stalk region. Background CLEC9A antibody, 1F6, recognizes C-type lectin domain family 9 member A (CLEC9A), also known as CD370 and DNGR-1. CLEC9A is a type II transmembrane glycoprotein that belongs to the C-type lectin superfamily. In mice and humans, CLEC9A is expressed by CD8a+ conventional dendritic cells (cDCs) in mice1,2 and BDCA3+ DCs in humans3, which are specialized for the cross-presentation of exogenous antigens on MHC class I4. In mice, type I interferon (IFN)-secreting plasmacytoid DCs (pDCs) also express CLEC9A2. The ligand for CLEC9A is filamentous actin exposed on apoptotic cells5,6, and ligation of CLEC9A results in the cross-presentation and induction of CD8 T cell responses. CLEC9A is a target for vaccine enhancement, and antibodies targeting CLEC9A in vaccination studies lead to enhanced presentation by DCs, eliciting CD8 and CD4 T cell proliferation and strong humoral immunity Antigen Distribution CD370 (CLEC9A) in mice is expressed on CD8+ DCs and at low levels by plasmacytoid DCs NCBI Gene Bank ID Research Area Immunology . Innate Immunity Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. The most common in vivo applications of clone 1F6 in mice are the identification, tracking, depletion, and functional analysis of CD8⁺ conventional dendritic cells (cDCs) through its specific binding to the mouse protein CLEC9A/DNGR-1/CD370. Key in vivo applications include:
Clone 1F6 is prized for its ability to distinguish CD8⁺ dendritic cells in mice, making it a useful tool for a range of in vivo immunological experiments, particularly those focused on dendritic cell biology, cross-presentation, and immune modulation. Several antibodies and proteins are commonly used with or alongside 1F6 in the literature, depending on the target protein or the context (e.g., amyloid-beta research, interleukin studies, or specific protein targets like neurocan). When 1F6 refers to the IL-36 alpha/IL-1F6 antibody, the following are frequently used:
For context where 1F6 denotes a different antigen (such as amyloid-beta or neurocan):
Summary Table: Commonly Co-Used Antibodies with 1F6
If you have a specific disease area or protein application in mind, please clarify, as the 1F6 clone/epitope can refer to different antibodies depending on context. The IL-36 context is most common for citations using “1F6” regarding inflammatory cytokines. I don't have specific information about "clone 1F6" citations in the provided search results. The search results contain general information about DNA cloning history, cloning techniques, and citation metrics in scientific literature, but they do not reference any specific clone designated as "1F6." To provide you with accurate information about clone 1F6, I would need search results that specifically discuss this particular clone. Clone 1F6 could refer to:
If you're looking for information about a specific clone 1F6 from a particular research context (such as immunology, molecular biology, or cell culture), please provide additional details about the research area or the original study where this clone was described. This would help in locating the relevant scientific literature and citations associated with that specific clone. There is no direct information in the provided search results about the dosing regimens of clone 1F6 across different mouse models. None of the sources specifically mention clone 1F6 or its dosing schedules in vivo or in any experimental mouse strains. Most results address general principles of antibody dosing, examples with other clones, or unrelated pharmacological agents. Essential context and supporting details:
Additional Relevant Information:
Summary Table (no regimen data for 1F6):
If your query aims to compare 1F6 with known clones like anti-CD115 (AFS98) or anti-IIb glycoprotein (6A6), detailed, model-specific dosing recommendations are available for those clones in the literature and may serve as approximate references. References & Citations1. Murphy KM, et al. (2012) Blood. 119(25):6052–62 2. Ahmet F, et al. (2008) Blood. 112(8):3264-3273 3. Brown GD, et al. (2008) J Biol Chem. 283(24):16693-701 3. Bevan MJ, et al. (2000) J Exp Med. vol. 192 (pg. 1685-1696) 4. Feest C, et al. (2012) Immunity. 36(4):635–45 5. Kitsoulis S, et al. (2012) Immunity. 36(4):646–57 6. Huang Y, et al. (2011) PNAS. 108(6):2384–9 7. Chan CEZ, et al. (2017) 2:31 8. Joffre OP, et al. (2010) Eur J Immunol. 40(5):1255–65 10. Lahoud M., et al. (2015) Eur. J. Immunol. 45:854–864 11. Caminschi I., et al. (2011) J Immunol. 187(2):842-50 12. Reis e Sousa C., et al. (2008) J Clin Invest. 118(6):2098-110 Technical ProtocolsCertificate of Analysis |
Formats Available
